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Abstract
Background: No study has evaluated C-reactive protein (CRP) and plasma albumin (PA) levels longitudinally in
patients with acute myeloid leukaemia (AML).
Methods: We studied defined events in 818 adult patients with AML in relation to 60,209 CRP and PA measures.
We investigated correlations between CRP and PA levels and daily CRP and PA levels in relation to AML diagnosis,
AML relapse, or bacteraemia (all ±30 days), and death (─30–0 days).
Results: On the AML diagnosis date (D0), CRP levels increased with higher WHO performance score (PS), e.g.
patients with PS 3/4 had 68.1 mg/L higher CRP compared to patients with PS 0, adjusted for relevant covariates. On
D0, the PA level declined with increasing PS, e.g. PS 3/4 had 7.54 g/L lower adjusted PA compared to PS 0. CRP and
PA levels were inversely correlated for the PA interval 25–55 g/L (R = − 0.51, p < 10–5), but not for ≤24 g/L (R = 0.01,
p = 0.57). CRP increases and PA decreases were seen prior to bacteraemia and death, whereas no changes occurred
up to AML diagnosis or relapse. CRP increases and PA decreases were also found frequently in individuals,
unrelated to a pre-specified event.
Conclusions: PA decrease is an important biomarker for imminent bacteraemia in adult patients with AML.
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Background
The close monitoring of acute myeloid leukaemia
(AML) patients in routine care includes an array of
biochemical specimens, amongst these C-reactive pro-
tein (CRP) and plasma albumin (PA) that are performed
repeatedly during the course of AML. Although AML
comprises a group of heterogeneous diseases [1, 2], a
common feature is the patient’s higher susceptibility to
infectious complications, due to AML’s impact on the
immune system or to treatments such as chemotherapy
or stem cell transplantation [3]. Neutropenia-associated
infection is thus the most common cause of death for
patients with AML [1]. In real-life situations it may be
difficult to assess the impact of inflammation on specific
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events (e.g. AML diagnosis or treatment). Studies that
assess biomarker levels and their changes over time (lon-
gitudinal studies) around well-defined events such as
diagnosis, treatment, relapse, bacteraemia, or death may
help elucidate this.
There is an abundant literature on CRP as a sepsis
marker [4] whereas the literature on CRP in haemato-
logical cancer patients is much sparser [5]. In leukaemia
patients, we have only encountered few longitudinal stud-
ies on CRP levels, all with 63 patients or less [6–10].
Numerous studies show that hypoalbuminemia is in-
variably associated with a worse prognosis for a wide
range of diseases [11, 12]. Hypoalbuminemia has trad-
itionally been related to chronic conditions such as liver
failure, malnutrition, or protein losing enteropathy [13,
14]. However, reviews [12, 15–18] and studies in critic-
ally ill patients [19–26] indicate that PA may be more
important as an inflammatory biomarker, probably
mainly related to PA extravasation as a result of capillary
leakage. To our knowledge, no study has assessed the
PA level as a biomarker of infectious episodes or other
events in haematological cancer patients.
Longitudinal studies elucidate whether an abnormal
level of the biomarker reflects an acute or a chronic ail-
ment. We recently published longitudinal assessment
studies of CRP and PA levels before and after
community-acquired bacteraemia [27, 28]. Some of the
main findings in these studies were the high inverse cor-
relations between CRP and PA levels and changes. For
CRP, changes over time are probably more valid as a
mortality predictor than a single measurement [29], but
whether this also applies to other outcomes than mortal-
ity or to PA is unknown.
In this population-based retrospective study we were
able to combine clinical, biochemical, microbiological,
and vital status data for 818 AML patients with their 60,
209 specimens of CRP and PA. Using CRP as a gold
standard inflammatory biomarker in these patients with
AML, we determined three aims of the study: i) to relate
CRP and PA levels to patient characteristics on the day
of AML diagnosis; ii) to describe correlations between
CRP and PA levels; and iii) to assess whether changes of
daily CRP and PA levels were related to diagnosis, treat-
ment, relapse, bacteraemia, and death.
Methods
Setting
In Denmark, the public health system is tax-financed
and consequently free of charge for the individual pa-
tient and the very few private hospitals are not engaged
in management of haematological cancer. All adult (≥15
y) patients with AML are treated in highly specialized
haematology departments in tertiary hospitals, which
have geographically well-defined catchment areas.
Derivation of the study cohort
All Danish residents have a unique civil registration
number used for all health contacts, which enables link-
age between registries [30].
The Danish National Acute Leukemia Registry
comprises patients with AML from January 2000,
with prospectively recorded clinical and patient-
related variables [31]. The AML diagnosis was veri-
fied when patients were registered in the database
and were based on WHO-defined criteria of blast
percentage in bone marrow or blood as well as spe-
cific cytogenetic and molecular aberrations [32, 33].
The day of diagnosis (D0) was defined as the day of
retrieval of the bone marrow biopsy. The database
covers 99.6% of all Danish adult patients with AML,
with 90–100% positive predictive values and com-
pleteness for almost all assessed variables [34]. From
this registry, we retrieved all patients with AML who
were followed at the Department of Haematology,
Odense University Hospital (OUH), diagnosed from
January 2000 through 17 May 2017 (last update at
data retrieval). This department has the Region of
Southern Denmark (~ 1,221,000 residents) [35] as its
catchment area.
We linked data from these patients to the following
registries: the Danish National Patient Registry
(DNPR) [36], the Danish Civil Registration System
(DCRS) [30], biochemistry laboratory information sys-
tems (Netlab (Medasys S.A., Littau, Switzerland), BCC
(www.cgi.dk/da), LABKA [37]), the OUH Patient Ad-
ministrative System, and the microbiology laboratory
information system MADS [38].
From the DNPR we retrieved comorbidity (excluding
haematological cancers) from 1977 (first year of DNPR
coverage) up to the patient’s AML diagnosis, as catego-
rized by the Charlson Comorbidity Index [39].
We used the DCRS to retrieve the vital status as per
24 November 2017 (alive, dead, disappeared, or emi-
grated, including dates of the latter three).
From biochemical specimens recorded in the labora-
tory information systems we retrieved results for CRP
and PA from January 2000 through 2017.
All blood cultures (BCs) were submitted to one of the
four clinical microbiology departments (OUH, Hospital
of Southern Jutland, Hospital Lillebaelt, Hospital of
South West Jutland) in the Region of Southern
Denmark. We had data on positive BCs covering 2000–
2016, though for 2000–2006 we only had data on BCs
submitted to OUH. OUH recorded results in the OUH
Patient Administrative System until 2005 and in MADS
thereafter, whereas the other three clinical microbiology
departments used MADS only.
We computed bacteraemic episodes from all positive
BCs, using globally defined criteria [40].
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Analyses of CRP and PA levels
CRP was measured with an immune-turbidimetric
principle on modular P® (Roche, Mannheim, Germany).
PA was measured on modular P® (Roche) by use of a
bromocresol green dye-binding method. All specimen
dates refer to date of draw of blood specimens.
Statistical analyses
The program Stata®, vs. 14, (StataCorp., College Station,
TX, USA) was used for all analyses, except Fig. 1 for
which R was used [41]. A two-sided p < 0.05 was consid-
ered statistically significant.
We only included dates of draw of blood specimens on
which both CRP and PA were measured. If more than one
measurement occurred on the same date we maintained the
lowest level of PA and the highest of CRP, thus computing a
specimen date as the analytical unit. A number of CRP results
were recorded as < 10mg/L (854/60,209 specimens [1.4%])
or < 5mg/L (1842 specimens [3.1%]). We therefore randomly
re-allocated all CRP levels < 10mg/L to range from 0 through
9mg/L, based on the distribution from 10 through 19mg/L
[27]. The same principle was used for CRP levels < 5mg/L
(range 0–4mg/L, based on the 10–14mg/L distribution).
Initially, we computed contingency tables of patient
characteristics on D0. To assess whether these charac-
teristics were associated with the CRP and PA levels on
D0 we performed linear regression analyses, with CRP
and PA on D0 as outcomes. We included sex, age group
(15–64, 65–80, + 80 y), body mass index (BMI) group in
kg/m^2 (< 18.5, 18.5–24.9, 25–29.9, ≥30, unknown),
Charlson comorbidity index (0, 1–2, > 2), WHO per-
formance status (PS) (0, 1, 2, 3/4) [42], neutrophil granu-
locytes in 10^9/L (< 0.5, 0.5–0.9, 1.0–1.4, ≥1.5, not
measured), and percent blasts in the bone marrow (0–
19, 20–39, 40–59, 60–79, 80–100, not measured) on D0
as independent covariates in crude analyses and in ana-
lyses adjusting for the same covariates.
To assess correlations between CRP and PA levels we com-
puted a smoothed scatterplot with CRP for each PA level (in-
tegers, ranging from 11 to 55 g/L, but 11–15 g/L merged with
16 g/L and 51–55 g/L merged with 50 g/L due to low num-
bers) as a separate category. After visual inspection of the scat-
terplot we computed Pearson’s correlation coefficients for all
specimens and separately for 11–24 and 25–55 g/L.
For each patient, a time line was computed, with D0
and dates for the following events assigned a day in rela-
tion to D0: first treatment after AML diagnosis, a bacter-
aemic episode, first AML relapse, and death. For all
patients we computed connected line plots with the CRP
level in mg/L or the PA level in g/L on the y-axis and
the time line (day in relation to D0) on the x-axis, with
vertical lines for the above events. We truncated these
connected line plots to only include results from 1 year
before D0. Because the first treatment after diagnosis
Fig. 1 Smoothed scatterplot of C-reactive protein and plasma albumin levels. A smoothed scatter plot of C-reactive protein levels (mg/L) in
relation to plasma albumin levels (ranging from 11 to 55 g/L, but 11–15 g/L merged with 16 g/L and 51–55 g/L merged with 50 g/L), based on
818 patients with 60,209 specimens in which both CRP and PA were measured. The smoothed colour displays the density of overplotted points
(red - > orange - > dark blue - > light blue represent decreasing density). The medians and 95% ranges of values are shown for each value of PA.
602 (1%) points from areas of lowest regional densities are plotted as small points
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was generally very close to D0 we omitted this event in
all subsequent analyses.
A clear inverse correlation between CRP and PA levels
was observed, both overall and for most of the individual
patients. This consistency enabled the merging of results
into daily mean CRP and PA levels up to and after the de-
fined events. PA levels were normally distributed, whereas
CRP levels were right skewed. In accordance with a previ-
ous study [27], longitudinal trajectories did not differ ac-
cording to whether medians (interquartile ranges) or
means (95% confidence intervals [CIs]) were used.
We therefore reported daily mean levels (95% CIs) of
PA and CRP, computed from 30 days before through 30
days after the following events: AML diagnosis, first bac-
teraemic episode after the AML diagnosis, and first
AML relapse. For patients who died, we computed daily
mean levels (95% CIs) of PA and CRP from 30 days be-
fore through date of death.
Because we wished to assess PA and CRP trajectories
around the selected events with as little impact as possible
from the other events, we made some exclusions. For the
AML diagnosis and relapse events, we excluded patients
who had a bacteraemic episode within 30 days in relation
to this event and death ≤30 days after the event. For the
AML diagnosis event we further determined that the first
bacteraemic episode should occur > 30 days after the
AML diagnosis date. For the bacteraemic episodes, we ex-
cluded patients if their bacteraemic episode occurred be-
fore the AML diagnosis, ≤30 days after the AML
diagnosis, within 30 days before or after the first AML re-
lapse, or ≤ 30 days before death. For death, we excluded
patients for whom AML diagnosis, AML relapse, or bac-
teraemia occurred ≤30 days before death.
Because more severely diseased patients were likely to have
more specimens taken, confounding by indication was an im-
portant consideration. Hence, to evaluate the robustness of
our results we did two things. Firstly, we computed the num-
ber of specimens per day in the − 30/30 day interval. Secondly,
to assess whether patients with more specimens contributed
unequally to the results, we reiterated all plots of mean levels
(95% CIs) by only including each patient’s first or last speci-
men within the day intervals − 30/− 1, 0, and 1/30.
Results
Patient characteristics on D0
Table 1 shows patient characteristics on D0. A total of 818 pa-
tients were diagnosed with AML between January 2000 and
May 2017. Four-hundred and eight patients had 782 bacter-
aemic episodes, 749 (95.8%) of which occurred on or after D0
and 583 of these (77.8%) occurred ≤1 year after D0 (data not
shown). Among the 491 bacteraemic episodes from 2007
through 2016, 452 (92.1%) were detected at the Department
of Clinical Microbiology, OUH (data not shown).
Table 1 Characteristicsa of 818 patients with acute myeloid
leukaemia (AML)
Text Number (%)b
Females 373 (45.6)
Males 445 (54.4)
Age, years
Range 15.2–95.6
Median (interquartile range) 69.4 (59.3–76.8)
Charlson comorbidity index
0 434 (53.1)
1–2 270 (33.0)
> 2 114 (13.9)
No. bacteraemic episodes
0 410 (50.1)
1 215 (26.3)
2 93 (11.4)
3 61 (7.5)
4 20 (2.4)
5–9 19 (2.3)
Microbiological isolates, first bacteraemic episode
Mono-microbial Gram-positive 349 (42.7)
Staphylococcus aureus 27 (3.5)
Coagulase-negative staphylococci 112 (14.3)
Streptococcus pneumoniae 12 (1.5)
Streptococci, other 10 (1.3)
Enterococcus faecalis 134 (17.1)
Other 54 (6.9)
Mono-microbial Gram-negative 308 (37.7)
Escherichia coli 127 (16.2)
Klebsiella spp. 53 (6.8)
Pseudomonas aeruginosa 30 (3.8)
Other 98 (12.5)
Mono-microbial fungi 18 (2.3)
Poly-microbial 107 (13.7)
Neutrophil granulocytes (10^9/L)
< 0.5 182 (22.2)
0.5–0.9 78 (9.5)
1.0–1.4 44 (5.4)
≥ 1.5 215 (26.3)
Not measured 299 (36.6)
Bone marrow biopsy blast percentage
0–19 14 (1.7)c
20–39 283 (34.6)
40–59 182 (22.3)
60–79 154 (18.8)
80–100 132 (16.1)
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Linear regression analyses for CRP and PA on D0
Results for the 491 patients (60.0%) with both CRP and PA
measured on D0 are shown in Table 2, which presents asso-
ciations between patient characteristics, CRP, and PA at D0.
Regardless of significance, covariates with negative co-
efficients for CRP had positive coefficients for PA and
vice versa, except for age groups.
For CRP levels, results were similar in subgroups of
sex, age, BMI, Charlson comorbidity index, neutrophil
categories, and blast percentage categories, both in crude
and adjusted analyses. A clear trend of increasing CRP
on D0 was associated with increasing WHO PS, with im-
material differences between the crude and adjusted co-
efficients. Thus, patients with WHO PS 3/4 had an
adjusted level of + 68.1 mg/L CRP in comparison to pa-
tients with WHO PS 0.
PA levels were similar in the same subgroups as the
CRP levels, except that it declined with increasing age
group and WHO PS, with little differences between
crude and adjusted analyses. Patients with WHO PS 3/4
had an adjusted PA level of − 7.54 g/L compared to pa-
tients with WHO PS 0.
Correlations between CRP and PA levels
After merging PA levels of 11–15 g/L (n = 39) with 16 g/
L (n = 53) and PA levels of 51–55 g/L (n = 47) with 50 g/
L (n = 49) we computed Fig. 1, which comprises 60,209
specimens. For these 60,209 specimens, the correlation
coefficient R was − 0.54 (p < 10− 5), but as Fig. 1 shows,
this inverse correlation was mainly seen in the range
25–55 g/L, for which R was similar (− 0.51, p < 10− 5, n =
56,796). For the remaining 3413 specimens, ranging
from 11 through 24 g/L, no correlation was found be-
tween the CRP and PA levels (R = 0.01, p = 0.57).
CRP and PA level trajectories for individual patients
Fig. 2 shows CRP (left column) and PA level (right col-
umn) trajectories for three patients randomly retrieved
among patients with the following events: ≥1 bacter-
aemic episode, AML relapse, and death. All trajectories
were truncated to their earliest CRP/PA measurement
≤1 year before D0.
Patient 101 (upper row) had three bacteraemic epi-
sodes on D74, D146, and D217 (vertical solid lines), an
AML relapse on D217 (vertical dashed line), and died on
D264 (vertical solid line on the right). Patient 127 (mid-
dle row) had two bacteraemic episodes (D61, D258), an
AML relapse on D231, and died on D270. Patient 170
(lower row) had three bacteraemic episodes (D15, D383,
D674), an AML relapse on D650, and died on D1264.
CRP levels (left column) generally increased around
bacteraemic episodes and prior to death, whereas fewer
fluctuations were detected around AML-related events
(diagnosis or relapse), although this may be difficult to
detect visually for patient 170, because these events were
close to two bacteraemic episodes. There were also CRP
increases for which we were not able to determine an
event that led to this, e.g. patient 101 around D30 and
patient 170 around D100 and D1150. CRP was generally
close to 0 mg/L in between its fluctuations.
PA (right column) fluctuated inversely to CRP, i.e.
when CRP increased, PA declined and vice versa, both
related and unrelated to the shown events.
Visual inspection of trajectory patterns for all 818 pa-
tients (data not shown) generally showed the same pat-
terns as described for the above three patients. This,
together with the high inverse correlations between CRP
and PA levels for PA levels ≥25 g/L, enabled the feasibil-
ity of computing CRP and PA level trajectories for the
aggregated study population.
Trajectories around main events for aggregated data
Table S1 shows number of patients and specimens used
for computing the trajectory curves for the aggregated
data in the time span from 30 days before through 30
days after the event (except − 30/0 days for death). Fig-
ure S1 shows number of specimens per day within the
same time spans.
Table 1 Characteristicsa of 818 patients with acute myeloid
leukaemia (AML) (Continued)
Text Number (%)b
Not measured 53 (6.5)
Intended treatment at AML diagnosis
Curative chemotherapy 501 (61.3)
Palliative chemotherapy 91 (11.1)
Best supportive care 218 (26.7)
Unknown 8 (1.0)
Vital status 1 y after the AML diagnosis date
Deceased 439 (53.7)
Alive 372 (45.5)
Unknownd 7 (0.9)
Vital status 2–5 y after the AML diagnosis date
Deceased 215 (57.8)e
Alive 96 (25.8)e
Unknownf 61 (17.5)e
aOn date of AML diagnosis, except for no. bacteraemic episodes and vital
status data
bExcept for “Age, years”, cf. text
cThese 14 patients had an extra-medullary AML location
dLess than 1 year between diagnosis date and latest vital status date (24
November 2017) on which they were alive
eDenominator is the 372 patients who were alive 1 year after the AML
diagnosis date
fLess than 5 years between diagnosis date and latest vital status date (24
November 2017) on which they were alive
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Table 2 Linear regression analyses of C-reactive protein and plasma albumin levels as dependent variables and patient
characteristics as explanatory variables on date of diagnosis of acute myeloid leukaemia (AML), based on 491 specimens with both
CRP and PA measured
Patient
characteristics
on date of
diagnosis of
AML
C-reactive protein Plasma albumin
Crude analysis Adjusted analysisa Crude analysis Adjusted analysisa
Sex
Females 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Males 3.80 (−10.5/18.1)b 1.78 (− 12.1/15.7) −1.00 (− 2.10/0.10) − 1.01 (− 2.02/0.00)
Age group, years
15–64 1 (reference) 1 (reference) 1 (reference) 1 (reference)
65–80 5.76 (−9.97/21.5) 1.29 (−14.9/17.5) −2.01 (− 3.18/−0.84)c −1.15 (− 2.32/0.02)
+ 80 −3.60 (− 24.1/16.9) − 16.5 (− 37.6/4.57) −4.46 (−5.99/− 2.94) − 2.76 (− 4.28/− 1.24)
Body mass index (kg/m^2)
< 18.5 −15.3 (−60.4/29.9) −19.1 (−63.4/25.1) −3.32 (−6.78/0.14) − 2.54 (− 5.73/0.65)
18.5–24.9 1 (reference) 1 (reference) 1 (reference) 1 (reference)
25–29.9 4.12 (− 14.0/22.2) 4.36 (−13.5/22.2) 0.31 (− 1.07/1.70) 0.08 (− 1.21/1.37)
≥ 30 −8.81 (−30.6/13.0) −6.27 (− 27.6/15.0) 1.33 (− 0.34/3.00) 0.74 (− 0.80/2.28)
Unknown 30.6 (10.7/50.6) 17.3 (−2.84/37.4) − 2.20 (− 3.72/− 0.67) − 0.26 (− 1.71/1.20)
Charlson comorbidity index
0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
1–2 5.68 (− 10.3/21.7) 5.05 (− 11.2/21.3) − 1.23 (− 2.46/0.01) − 0.33 (− 1.50/0.84)
> 2 8.07 (− 13.5/29.6) −2.91 (− 24.7/18.9) −1.89 (− 3.54/− 0.25) 0.35 (− 1.23/1.92)
WHO performance status
0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
1 12.4 (− 6.02/30.8) 12.3 (− 6.40/31.0) −2.38 (− 3.73/− 1.03) −2.18 (− 3.53/− 0.84)
2 36.1 (13.6/58.6) 36.7 (13.1/60.3) −4.98 (− 6.63/− 3.34) − 4.21 (− 5.91/− 2.51)
3/4 74.9 (51.2/98.6) 68.1 (42.2/94.0) −8.41 (− 10.1/− 6.67) − 7.54 (− 9.41/− 5.67)
Neutrophil granulocytes (10^9/L)
< 0.5 1 (reference) 1 (reference) 1 (reference) 1 (reference)
0.5–0.9 10.7 (− 13.0/34.5) 5.01 (− 18.0/28.1) − 0.19 (− 2.00/1.62) 0.65 (−1.02/2.31)
1.0–1.4 15.1 (−14.2/44.5) 1.25 (− 27.2/29.7) − 0.55(− 2.79/1.68) 0.55 (− 1.51/2.60)
≥ 1.5 17.9 (0.37/35.5) 10.1 (−7.22/27.3) −2.16 (− 3.50/− 0.82) −1.10 (− 2.34/0.15)
Unknown 11.7 (− 11.8/35.2) 1.96 (− 20.9/24.9) −2.73 (− 4.52/− 0.94) −2.00 (− 3.65/− 0.34)
Blast percentage, bone marrow biopsy
0–19 1 (reference) 1 (reference) 1 (reference) 1 (reference)
20–39 18.1 (− 61.1/97.2) 31.1 (− 46.3/109) 3.71 (−2.48/9.90) 2.49 (− 3.10/8.08)
40–59 21.9 (− 57.8/102) 31.9 (− 46.0/110) 2.91 (− 3.32/9.14) 1.65 (− 3.98/7.28)
60–79 31.0 (− 48.7/111) 40.9 (− 36.9/119) 3.73 (− 2.51/9.96) 2.18 (− 3.43/7.80)
80–100 52.4 (− 27.5/132) 63.0 (− 15.2/141) 3.58 (− 2.66/9.83) 2.05 (− 3.60/7.69)
Unknown 62.1 (−21.2/145) 55.6 (− 25.4/137) 2.28 (− 4.22/8.79) 2.96 (− 2.89/8.81)
aAdjusted for all covariates in Table 2
bCoefficient (95% confidence interval)
cBold types: statistically significant (p < 0.05)
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CRP level trajectories for aggregated data around
diagnosis, relapse, bacteraemia, and death
CRP levels showed no clear trend of increases or de-
creases during the 30 days up to the diagnosis date
(Fig. 3, upper row, left side). Most of the mean CRP
levels ranged from 55 to 95mg/L in this period. There
were no conspicuous changes in mean CRP levels when
AML was diagnosed, but a minor increase started about
7 days thereafter, continuing to day 20 after which it de-
clined again.
Fig. 2 Trajectories of C-reactive protein and plasma albumin levels for three patients. Trajectories of levels of C-reactive protein (CRP) in left
column and plasma albumin (PA) in right column for three individual patients (designated patient 101, 127, and 170, using encrypted
identification numbers). Date of diagnosis of acute myeloid leukaemia (AML) is designated day 0 (D0) on the x-axis (with a solid vertical blue line)
and all other days on the x-axis are depicted in relation to D0. The right-most solid vertical black line shows day of death. In between D0 and
date of death, solid vertical green lines show day of diagnosis of a bacteraemic episode and the dashed blue line shows day of relapse of AML.
All trajectories exclude specimens retrieved > 365 days before D0. For PA, the horizontal line of 35 g/L shows the threshold between
normoalbuminemia (≥35 g/L) and hypoalbuminemia (< 35 g/L)
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Fig. 3 (See legend on next page.)
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For AML relapses, trajectories before these events
showed no clear changes (Fig. 3, second upper row, left
side) where most of the mean CRP levels ranged from
40 to 80mg/L. Approximately 15 days after the relapse,
CRP levels started to increase, with a peak of ~ 100 mg/
L 30 days thereafter.
Mean CRP levels were steadily around 55mg/L before a
first-time bacteraemic episode (Fig. 3, second lower row,
left side). On the bacteraemia date, it increased to ~ 100
mg/L, reaching a peak of ~ 160mg/L 2 days later, after
which it declined steadily, reaching a level of ~ 70mg/L
30 days after the episode.
Mean CRP levels 30–14 days before death were rela-
tively high (100–110mg/L), but with no clear trend of in-
creases or decreases (Fig. 3, lower row, left side). About
14 days before death, a clear increase commenced, termin-
ating in mean levels of ~ 190mg/L around death.
PA level trajectories for aggregated data around
diagnosis, relapse, bacteraemia, and death
In the 30 days up to the diagnosis date, mean PA levels
fluctuated around 35 g/L, with no clear trend of in-
creases or decreases (Fig. 3, upper row, right side). A de-
cline commenced the day after diagnosis, continuing to
a steady level of ~ 31 g/L about 20 days later.
The trajectories around AML relapses (Fig. 3, second
upper row, right side) did not deviate materially from
those described for the primary AML diagnosis.
Before the first bacteraemic episode, mean PA levels
were steadily around 33–34 g/L (Fig. 3, second lower row,
right side). It declined on the bacteraemia date, reaching a
nadir of ~ 31 g/L 2 days thereafter, after which a slow in-
crease commenced, though pre-bacteraemic levels were
not reached 30 days after the bacteraemia date.
Before death, the mean PA levels were steadily around
31 g/L until 14–17 days before, where a decline com-
menced (Fig. 3, lower row, right side). On the date of
death, a mean level of ~ 27 g/L was reached.
Comparisons between CRP and PA level trajectories for
aggregated data
The inverse correlations between CRP and PA levels de-
scribed above for cross-sectional data (Fig. 1) and for in-
dividual patients (Fig. 2) were in the longitudinal data
descriptions also seen around bacteraemia and AML re-
lapse, and before death, but were less consistent around
AML diagnosis. Treatment data (Table 1) enabled the
computation of Figure S2, which shows a decline in PA
levels after diagnosis/treatment, both for curative and
palliative treatments, whereas no decline was seen if best
supportive care was given. For CRP, we computed simi-
lar figures in relation to treatment modality, but there
were no conspicuous differences between these trajec-
tories (data not shown).
Reiteration of trajectory plots with each patient’s first or
last specimen
The inclusion of each patient’s first or last specimen
within each of the three periods day − 30/− 1, day 0, and
day 1/30 in relation to the event reduced the numbers of
specimens considerably (Table S1). Due to this, many
trajectory curves had very wide CIs (data not shown).
There were, however, no conspicuous deviations from
the trajectories depicted in Fig. 3 (data not shown).
Discussion
We found high inverse correlations between CRP and PA
levels in 818 adult patients with AML. On D0, the linear
regression analyses showed minor differences between the
univariate and multivariate analyses, which corroborate
our results. In cross-sectional analyses of all 60,209 speci-
mens, R was − 0.54 (p < 10− 5), though a threshold of 24 g/
L PA was detected below which no correlation was found.
In longitudinal analyses, increasing CRP levels and de-
creasing PA levels were detected around bacteraemic epi-
sodes and prior to death, but also frequently unrelated to
events defined beforehand in our study population. In
contrast, minor changes in CRP and PA levels were found
in relation to AML events (diagnosis or relapse), with the
exception that PA levels decreased after diagnosis.
We used the CRP level as a gold standard measure of
the magnitude of inflammation. Moreover, a bacteraemic
episode is an infection based on well-defined microbial
and globally accepted criteria [40]. In order to more
closely assess “pure” infection-related, AML-related, and
death-related events in the longitudinal analyses we ex-
cluded other events types occurring within 30 days.
Our main hypothesis was that PA is an inflammatory
biomarker. This was indicated due to its inverse correl-
ation with CRP levels and in relation to its rapid changes
over a few days that cannot be explained by a change of
the patient’s nutritional status or chronic ailments, also
given PA’s long half-life of 20 days [43]. Moreover, PA
was not correlated to BMI at diagnosis, which
(See figure on previous page.)
Fig. 3 Daily mean levels of C-reactive protein and plasma albumin, aggregated data. Daily mean levels (95% confidence intervals) of C-reactive
protein (CRP) in left column and plasma albumin (PA) in right column, in relation to an event (vertical solid line). Events are, from top to bottom:
diagnosis of acute myeloid leukaemia (AML), relapse of AML, first bacteraemic episode, and death. Time spans covers from 30 days before to 30
days after the event, except for death that shows 30 days before death. Events occurring earlier than 30 days in relation to another event
were excluded
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corroborates that it is not a useful biomarker of nutri-
tion [12, 15–18]. Interestingly, the inverse correlations
between CRP and PA levels were clearly depicted
with increasing WHO PS. WHO PS is, regardless of
disease entity, a strong prognostic predictor and fur-
ther refinement by the incorporation of CRP and PA
levels/changes deserves further attention. In recent
years, indices based on CRP and PA levels, such as
the Glasgow Prognostic Score [44] or the CRP/PA ra-
tio [45], have shown high prognostic predictability for
several cancer types. However, the numerous studies
focused on solid cancers, they were cross-sectional,
and revealed little about possible mechanisms related
to the prognostic predictability [44, 45].
Although PA as an inflammatory biomarker was a main
finding due to its inverse correlations with CRP levels and
changes, other mechanisms were probably also involved in
hypoalbuminemia: no correlations between PA and CRP
levels were seen for PA < 24 g/L and PA levels decreased
shortly after the diagnosis of AML, unparalleled by in-
creasing CRP levels. The latter was explored for treatment
subgroups (curative treatment, palliative treatment, best
supportive care), indicating that fluid therapy given during
treatment could explain this (Figure S2).
Already in 1863, Rudolf Virchow detected leukocytes
in neoplastic tissues and thus found a connection be-
tween cancer and inflammation [46]. In 1986, Dvorak
described tumours as “wounds that do not heal” [47].
During the last two decades, the research field of cancer
and inflammation has experienced a renaissance [46, 48,
49]. A review concluded that cancer patients generally
had higher CRP levels than controls [50], but as 81 of
the 90 studies were cross-sectional we do not know
whether the higher CRP levels occurred before the can-
cer or vice versa.
Smaller studies of longitudinally measured CRP in leukae-
mia patients (n= 20–63) found that CRP levels > 100mg/L
correlated temporally with infectious episodes [6–10]. Some
of these studies also assessed CRP levels in leukaemia relapse
episodes, which were generally much lower than 100mg/L
[6, 7, 9]. To our knowledge, no study has assessed PA as a
biomarker of infectious or cancer episodes in haematological
cancer patients, or in any other cancer patient group.
In the present study, the CRP and PA trajectories
around the bacteraemic episodes did not deviate from
what we have reported for 2472 adult community-
acquired bacteraemia patients [27]. This indicates that
the pathogenesis related to CRP and PA changes around
a bacteraemic episode probably does not differ in rela-
tion to the patient group or the degree of immunosup-
pression. Moreover, much smaller or no CRP and PA
changes were detected around AML-related events,
which accordingly had little impact on changes around
the bacteraemic episodes.
For the AML-related events, the interpretation of the
longitudinal CRP and PA trajectories is less straightfor-
ward than for the bacteraemic episodes. Firstly, due to
low numbers of specimens, caution in interpretation is
especially warranted up to the diagnosis and around the
relapse. Secondly, although we excluded diagnosis or re-
lapse events for which a bacteraemic episode occurred
within 30 days we also found numerous CRP increases
and PA decreases that were temporally unrelated to a
bacteraemic episode (Fig. 2). This is also found in studies
with many non-bacteraemic infectious episodes detected
from medical records [6–10]. Thus, other infections than
bacteraemia occur close to AML-related events in our
study. In spite of these caveats, there were little changes
in CRP and PA levels around the AML-related events.
The inverse correlations between CRP and PA levels
were also seen in the last 14 days up to death. Even before
this 2-week period, mean CRP levels were above 100mg/
L, indicating an ongoing inflammation, and mean PA
levels were ~ 30 g/L (i.e. hypoalbuminemia). A recent
Swedish study assessed CRP and PA levels up to the death
of 155 incurable cancer patients [51]. Though numerous
studies have assessed biomarkers of mortality in cancer
patients [52], no other study has to their (and our) know-
ledge assessed CRP and PA levels in the last 2 months be-
fore patients’ death. In the Swedish patients, the median
CRP and PA levels in the last month before death were
84mg/L and 23 g/L, respectively. In our study, 654 pa-
tients with 5739 CRP/PA specimens in the last month be-
fore death had median CRP and PA levels of 108mg/L
and 29 g/L, respectively (data not shown), thus higher
CRP and PA levels. Most of the Swedish patients had a
broad spectrum of solid tumours, which may in part ex-
plain these discrepancies. Unfortunately, the Swedish
study did not report longitudinal trajectory patterns,
which further hampers comparisons to our study.
In this hypothesis-generating study we have mainly re-
ported descriptive results. We purportedly have not re-
ported discriminatory measures (e.g. sensitivity or
positive predictive values). This is mainly due to our def-
initions, which are not globally defined, and the lack of
accurate detection of non-bacteraemic infectious epi-
sodes. We had data for all the patients’ hospital admis-
sions as from 1977 and their outpatient visits as from
1995, each with all recorded diagnosis codes [36]. Al-
though the validity of recorded infections may be satis-
factory (high positive predictive values as reviewed by
[36]) it is dubious whether all infections are recorded in
the administrative registries. As only 32.3% of 58,139
bacteraemic episodes were recorded properly in the
DNPR [53], milder, and less well-defined, infections were
probably even recorded less.
The main strengths of this study are the population-
based design (including virtually all adult patients with
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AML from a geographically well-defined region),
complete follow-up, and the high number of patients
and specimens. Previous studies on longitudinal CRP
analyses in leukaemia patients have included 20–63 pa-
tients [6–10] and our study is the first to assess PA. The
high number of patients and specimens enabled longitu-
dinal analyses and a two-stage approach in which we
first assessed all 818 patients individually and thereafter
aggregated their data. Clinically relevant variables of
high validity and with few missing values [34] were avail-
able at the time of the AML diagnosis. We had valid
data on bacteraemic episodes, representing well-defined
and globally accepted criteria [40].
Our study also has important limitations. Firstly, most
studies that evaluate biomarkers longitudinally are pro-
spective, which enables the retrieval of the same num-
bers of specimens from all patients, regardless of their
current health status. In our retrospective study with its
real-life data we expect more specimens from patients
with complications, thus confounding by indication may
be a concern. This was the main reason for reiterating
analyses by the incorporation of each patient’s first or
last specimen within pre-specified periods. This did not
alter the trajectories materially (data not shown), which
is also in accordance with our recent study focusing on
this particular aspect [28]. Secondly, non-bacteraemic in-
fectious episodes were not defined and as stipulated
above we do not believe this can be done validly from
administrative registries, such as the DNPR. Moreover,
patients with AML frequently receive prophylactic anti-
biotics and antimycotics, which will often result in
culture-negative microbiological specimens although
they clearly have an infection. Thirdly, though the gen-
eral number of specimens was high, it was low before
the AML diagnosis and around AML relapse. Prior to
diagnosis of an acute disease, such as AML, it will prob-
ably even to a higher degree than described above be the
frailer patients from whom specimens are retrieved due
to several other reasons than AML per se. Thus, trajec-
tories before the AML diagnosis should be interpreted
with extra caution, whereas they are probably more rep-
resentative for the whole study population in the time
period adjacent to and after the diagnosis. Fourthly, we
had few clinical variables after the time of diagnosis, of
which e.g. BMI and antibiotic/anti-fungal treatment
could have been interesting to follow longitudinally. Fi-
nally, from 2000 through 2006 we only had microbio-
logical data from OUH, covering 291 bacteraemic
episodes. As 452 of the 491 bacteraemic episodes
(92.1%) in 2007–2016 were from OUH, we “missed” ~
30 episodes given the same distribution between OUH
and the other three clinical microbiological departments
in 2000–2006. Moreover, 10 patients had AML diag-
nosed in 2017 from which we had no BC results.
However, these estimated “missed” 35 bacteraemic epi-
sodes (4.5%) will have very little impact on our results.
Conclusions
The PA level is an important inflammatory biomarker in
adult patients with AML. The incorporation of the PA
level, together with the CRP level, in mathematically
well-founded prediction models deserves further atten-
tion. Models that will be able to predict infections or
death will be useful for clinicians, both for AML and
other immunocompromised patients.
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